Chronic myeloid disorders: Classification and treatment overview

Seminars in Hematology

Volumn 38, Issue 1 SUPPL. 2, 2001, Pages 1-4

  Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BUSULFAN; CORTICOSTEROID; CYTARABINE; HYDROXYUREA; THALIDOMIDE;

BLOOD CELL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE CLASSIFICATION; EOSINOPHILIC LEUKEMIA; ERYTHROCYTE; HEMATOPOIESIS; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA 1 CHROMOSOME; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0035106754     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(01)90133-7     Document Type: Review

References (37)

1. Chronic myelocytic leukemia: Clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage
2. Chronic granulocytic leukemia: Recent information on pathogenesis, diagnosis, and disease monitoring
3. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: Developed for the American Society of Hematology
4. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group
5. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
6. Morphology and classification of the myelodysplastic syndromes and their pathologic variants
7. Clonal studies in the myelodysplastic syndrome using x-linked restriction fragment length polymorphisms
8. International scoring system for evaluating prognosis in myelodysplastic syndromes
9. Bone marrow transplantation for myelodysplasia
10. Mixed myelodysplastic and myeloproliferative syndromes
11. Clonality of isolated eosinophils in the hypereosinophilic syndrome
12. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis
13. Myelofibrosis with myeloid metaplasia
14. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center collaborative study
15. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival
16. Danazol treatment of idiopathic myelofibrosis with severe anemia
17. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea
18. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients
19. Effective treatment of myelofibrosis (MF) by autologous peripheral blood stem cell (PBSC) transplantation (PBSCT)
20. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia
21. Serious myeloproliferative reactions associated with the use of thalidomide in myelofibrosis with myeloid metaplasia
22. A clinical update in polycythemia vera and essential thrombocythemia
23. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
24. Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value
25. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: Immunoperoxidase staining patterns and clinical correlates
26. No treatment for low-risk thrombocythemia: Results from a prospective study
27. A long-term study of young women with essential thrombocythemia
28. Outcome analysis of 34 pregnancies in women with essential thrombocythemia
29. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
30. Long-term use of anagrelide in young patients with essential thrombocythemia
31. Essential thrombocythemias. Clinical evolutionary and biological data
32. Clinical course of essential thrombocythemia in 147 cases
33. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders
34. Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction
35. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935-1989
36. Polycythemia rubra vera